SBIR Phase II: Vertical Perifusion System for Cell Culture and Monitoring

SBIR II 期：用于细胞培养和监测的垂直灌注系统

• 批准号: 0750508
• 负责人: Michael Varney
• 金额: --
• 依托单位: TauTheta Instruments LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-15 至 2010-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0750508&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Vertical; Perifusion

This Phase II SBIR research develops tools to monitor live cells in a model system capable of maintaining the cells over extended periods in near normal conditions. The perfusion chamber allows one to interrogate the metabolic response of cells in real-time in a non-invasive manner. Potentially, this technology could open a number of tissues to examination in further detail for research and as an alternative to live animal testing.The broader impacts of this project include significant advances in the science of cell physiology and behavior, mechanistic pathways of diseases, and improved understanding of cellular signaling, growth and death. Rational design of more effective drugs depends on ever improving fundamental knowledge of cellular mechanisms. Commercially this innovation will lower the cost of drug development, testing and clinical trials, thereby providing broad benefit to the US healthcare industry.

该二期SBIR研究开发了一种工具来监测模型系统中的活细胞，该模型系统能够在接近正常的条件下长时间维持细胞。灌注室允许人们以无创的方式实时询问细胞的代谢反应。潜在地，这项技术可以打开许多组织，以进一步详细检查研究，并作为活体动物试验的替代方案。该项目的广泛影响包括在细胞生理学和行为科学、疾病的机制途径以及对细胞信号传导、生长和死亡的更好理解方面取得重大进展。合理设计更有效的药物取决于不断提高细胞机制的基本知识。在商业上，这一创新将降低药物开发、测试和临床试验的成本，从而为美国医疗保健行业带来广泛的利益。